Chronic obstructive pulmonary disease (COPD) and coronary artery disease (CAD) are global epidemics causing significant morbidity and mortality. There is a high coexistence between COPD and CAD given the fact that both conditions are systemic disorders with overlapping mechanisms and pathophysiologic processes besides common shared risk factors, primarily smoking and aging. Considering the expanding mortality and poor outcomes imposed by each disease, it is crucial to diagnose these two coexistent conditions. In order to establish and maintain a good management strategy on this issue, the effects of medications on each disease should be taken into account. Furthermore, drug interactions have a vital role in managing therapy. The usage of statins and inhaled corticosteroids in COPD has been investigated as potential drugs that may lower cardiovascular risk. On the other hand, multiple cardiovascular medications such as antiplatelet drugs, statins and renin-angiotensin system (RAS) blockers seem to be safe in COPD and even associated with beneficial effects in many respects. Cardioselective beta blockers are also safe drugs in COPD patients except for that requiring continuous oxygen therapy. As the clinicians often struggle to balance the risks and benefits of multiple recommended treatments, further studies conducted in patients with both COPD and CAD are needed..